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A generic two-step lyssavirus real-time reverse transcriptase polymerase chain reaction (qRT-PCR), based on a nested PCR strategy,
was validated for the detection of different lyssavirus species. Primers with 17 to 30% of degenerate bases were used in both
consecutive steps. The assay could accurately detect RABV, LBV, MOKV, DUVV, EBLV-1, EBLV-2, and ABLV. In silico sequence
alignment showed a functional match with the remaining lyssavirus species.The diagnostic specificity was 100% and the sensitivity
proved to be superior to that of the fluorescent antigen test. The limit of detection was ≤1 50% tissue culture infectious dose. The
related vesicular stomatitis virus was not recognized, confirming the selectivity for lyssaviruses. The assay was applied to follow
the evolution of rabies virus infection in the brain of mice from 0 to 10 days after intranasal inoculation. The obtained RNA curve
corresponded well with the curves obtained by a one-step monospecific RABV-qRT-PCR, the fluorescent antigen test, and virus
titration. Despite the presence of degenerate bases, the assay proved to be highly sensitive, specific, and reproducible.
1. Introduction
Rabies is a fatal viral encephalitis that results from infection
with negative strand RNA-viruses belonging to the genus
Lyssavirus, family Rhabdoviridae, orderMononegavirales. So
far, 12 species have been classified in the genusLyssavirus. Tra-
ditionally, these include Rabies virus (RABV), Lagos bat virus
(LBV), Mokola virus (MOKV), Duvenhage virus (DUVV),
European bat lyssaviruses-1 and -2 (EBLV-1 and EBLV-
2), and Australian bat lyssavirus (ABLV). More recently,
Aravan virus (ARAV), Khujand virus (KHUV) [1], Irkut
virus (IRKV) [1], Shimoni bat virus (SHIBV), and West
Caucasian bat virus (WCBV) [1] were also added. Ikoma
virus (IKOV) [2] and Bokeloh bat lyssavirus (BBLV) [3, 4]
await classification in the genus.The genus is subdivided into
phylogroups 1 and 2 [5, 6]. Phylogroup 1 includes RABV,
DUVV, EBLV-1, EBLV-2, ABLV, ARAV, KHUV, and IRKV.
Phylogroup 2 includes LBV, MOKV, and SHIBV. WCBV and
IKOV do not cross-react serologically with any of the two
phylogroups.
The classic rabies virus (RABV) has a worldwide distribu-
tion and uses carnivores and bats asmain reservoir.The other
lyssavirus species are mainly maintained in bats and have
a more restricted distribution: DUVV, LBV, MOKV, SHIBV,
and IKOV have been detected exclusively in Africa, EBLV-
1, -2 and BBLV in Europe, ABLV in Australia, and ARAV,
KHUV, IRKV, and WCBV in Asia. It is assumed that most
lyssaviruses can cause the rabies syndrome in humans and
other mammals [6–8]. In Western Europe, most cases of
rabies in humans or pets are imported and may be caused by
any species within the Genus Lyssavirus [9, 10]. For example,
in 2007, in The Netherlands, a patient died from infection
with the rare DUVV upon return from Kenya [11]. Moreover,
locally acquired infections in humans and cats with EBLV-1
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 256175, 12 pages
http://dx.doi.org/10.1155/2014/256175
2 BioMed Research International
Table 1: FAT and RTCIT-negative samples from various species used for the evaluation of the specificity of the lyssavirus qRT-PCR.
Species Matrix Provider 𝑛 FAT/RTCIT Generic lyssavirusqRT-PCR
Bats (Pipistrellus,Myotis, and
Eptesicus serotinus)1
Brain tissue Rabies NRC, WIV-ISP, Belgium 100 Negative Negative
Red Fox (Vulpes vulpes)1 Brain tissue Rabies NRC, WIV-ISP, Belgium 10 Negative Negative
Dog (Canis Lupus familiaris)1 Brain tissue Rabies NRC, WIV-ISP, Belgium 10 Negative Negative
Cat (Felix cati)1 Brain tissue Rabies NRC, WIV-ISP, Belgium 10 Negative Negative
Mouse (Mus Musculus)2 Brain tissue Rabies NRC, WIV-ISP, Belgium 20 Negative Negative
Human (Homo Sapiens)3 Cerebrospinal fluid Rabies NRC, WIV-ISP, Belgium 10 Negative Negative
Human (Homo Sapiens)3 Saliva Rabies NRC, WIV-ISP, Belgium 5 Negative Negative
Human (Homo Sapiens)3 Skin tissue Rabies NRC, WIV-ISP, Belgium 1 Negative Negative
1Samples collected on the Belgian territory between 2007 and 2012 in the frame of the national surveillance system to guarantee the rabies-free status of Belgium.
2Specific-pathogen-free female Swiss outbred laboratory mice obtained from Harlan (Boxmeer, The Netherlands).
3Patients with encephalitis symptoms sent to the national reference centre for rabies virus, Belgium.
or EBLV-2 are also possible on the European territory [12]. A
diagnostic assay that can rapidly detect all species is therefore
highly recommended.
Currently, the gold standard methods for the diagnosis
of rabies recommended by the World Health Organisation
(WHO) are the fluorescent antibody test (FAT), the rabies
tissue culture infection test (RTCIT), and the mouse inocula-
tion test (MIT) [13–18].TheFAT is convenient for postmortem
examination and detects the presence of viral nucleocapsid
antigens in the brain or spinal cord tissue by staining with
specific fluorescent antibodies [14]. For antemortemdiagnosis
of rabies, the presence of viral antigen can be detected
with the FAT in tissue sections of skin biopsies, typically in
the nerve endings surrounding the hair follicles. The viral
antigens are however often only detectable at the end of the
disease or cannot be detected at all by this method [17].
Repeated sampling is necessary to improve the diagnostic
sensitivity.This is not practical for skin biopsies [17] but easier
for body fluids, such as saliva, urine, or cerebrospinal fluid.
The sensitivity of the FAT method is considered high for
RABV but may be lower for other lyssavirus species [19–21].
RTCIT and MIT are based on the isolation and propa-
gation of virus, respectively, in cell culture or in mice [22].
Isolation of the virus from body fluids requires the presence
of infectious virus in the sample and the absence of viral
inhibitors or antibodies and is time consuming. Antirabies
virus antibodies acquired either by natural seroconversion,
by treatment with immunoglobulins, or after a postexposure
vaccination can interfere with the virus isolation from clinical
samples, possibly yielding false negative results in the RTCIT
andMIT. In our experience,MIT andRTCIT are very specific
methods but are restricted to samples containing live and
uninhibited virus. Furthermore, neither the FAT, RTCIT, or
MIT can directly distinguish between different lyssavirus
species. Seroconversion during the course of disease is highly
indicative for rabies, but patients often receive treatment
with antirabies immunoglobulins and vaccine, compromis-
ing the interpretation of serology. Molecular techniques have
recently been developed for rabies virus diagnosis. Viral RNA
can be extracted from several matrices, such as saliva, urine,
cerebrospinal fluid (CSF), or skin tissue, and do not require
the presence of live virus. RT-PCR can therefore be used
under a broad range of conditions. RT-PCR has been shown
to detect RNA in decomposed samples [23] or after long-term
storage [24], giving a better chance of successful diagnosis
than RTCIT [25]. Also, the qRT-PCR method can allow to
distinguish different lyssavirus species.
Here, we aimed to develop and validate a nested two-step
generic lyssavirus real-time RT-PCR (qRT-PCR) protocol,
combining the use of degenerate primers with real-time PCR
detection. A two-step approach was chosen to maximize the
sensitivity of the assay. Degenerate bases were included in
the primers at key positions to account for the variability
in the sequence of the different lyssavirus species. During
the first amplification round (PCR1), the primers amplified
a 343 bp fragment of the nucleoprotein N gene, whereas in
the following real-time PCR a 158 bp fragment was amplified
and detected using SYBR Green. The overall sensitivity,
specificity, selectivity, and reproducibility of the assay were
assessed by comparisonwith FAT.More specifically for RABV
detection, the performance of the generic lyssavirus qRT-
PCRwas comparedwith a RABV-specific qRT-PCR protocol,
using specific primers without degenerate bases. A large set of
samples obtained fromhumans, naturally and experimentally
infected wild and domestic animals were included to validate
the assay.
2. Materials and Methods
2.1. Samples
2.1.1. Negative Samples. Brain, serum, and cerebrospinal fluid
(CSF) samples from different species (bat, red fox, dog, cat,
mouse, and human) were used as negative controls (Table 1).
All samples tested negative for rabies in the FAT and/or
RTCIT gold standard methods. To further test for specificity,
a virus suspension of vesicular stomatitis virus (VSV) (genus
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Table 2: Rabies virus-positive samples used to assess the diagnostic sensitivity of the lyssavirus qRT-PCR.
Positive samples Provider Strain reference Matrix 𝑛
Classical rabies virus
RABV
ANSES, France1 Ariana, Tunisia Dog brain homogenate 3
ANSES, France1 CVS-27 Mouse brain homogenate 3
ANSES, France1 GS7, France Fox brain homogenate 7
ANSES, France1 Raccoon, Poland Raccoon dog brain homogenate 1
ANSES, France1 201020958, Spain Mouse brain homogenate 2
ANSES, France1 Cn Viv Estonie 10–12, Estonia Mouse brain homogenate 1
Rabies NRC, ISP-WIV Strain fox, Belgium (1995) Red fox brain homogenate 1
Rabies NRC, ISP-WIV Strain fox, Luxembourg (2000) Pony brain homogenate 1
Rabies NRC, ISP-WIV CB-1, Maroc (2007) Dog brain homogenate 1
ATCC, USA CVS-11 (VR959)
Mouse brain homogenate
(experimentally infected mice at
Rabies NRC, WIV-ISP, Belgium)
20
Lagos bat virus
LBV
Centre des Ressources
Biologiques, Pasteur Paris
Institute, France
CRBIP8.14 Cell culture lysate 1
Mokola virus
MOKV
Centre des Ressources
Biologiques, Pasteur Paris
Institute, France
CRBIP8.27 Cell culture lysate 1
Duvenhage virus
DUVV
ANSES, France1 96132, SA (fixed strain) Mouse brain homogenate 1
Centre des Ressources
Biologiques, Pasteur Paris
Institute, France
CRBIP8.28 Cell culture lysate 1
European bat lyssavirus-1
EBLV-1
ANSES, France1 EBLV-1a, France Mouse brain homogenate 3
ANSES, France1 EBLV-1b, France Mouse brain homogenate 4
WIV-ISP, Belgium2 AF-2010, Spain Bat brain homogenate (Naturallyinfected Eptesicus serotinus bat) 1
ANSES, France1 R75, Spain Mouse brain homogenate 1
Pasteur Paris Institute,
France3
8919FRA, France (isolated from
Eptesicus serotinus bat)
Mouse brain homogenate
(experimentally infected mice at
Rabies NRC, WIV-ISP, Belgium)
5
European bat lyssavirus-2
EBLV-2
ANSES, France1 EBLV-2 VLA P3, UnitedKingdom Mouse brain homogenate 1
ANSES, France1 EBL2 RV1787, United Kingdom Mouse brain homogenate 1
ANSES, France1 EBLV-2, United Kingdom Mouse brain homogenate 5
Australian bat lyssavirus
ABLV ANSES, France
1 ABLV, Australia Mouse brain homogenate 4
1Samples obtained through participation to consecutive an interlaboratory proficiency tests organised by the European Union reference laboratory of rabies
(ANSES, Nancy, France) between 2009 and 2013. Samples were reconstituted in 1mL sterile, nuclease-free, and distilled water (Robardet et al., 2011 [26]).
2Van Gucht et al., 2013 [27].
3Bourhy et al., 1992 [28].
Vesiculovirus) was also tested to demonstrate the selectivity of
the primers. VSV belongs to another genus within the family
Rhabdoviridae and shares biological and genetic featureswith
the lyssaviruses.
2.1.2. Positive Samples. To test the performance of the
generic lyssavirus qRT-PCR, samples spiked with different
lyssaviruses were used (Table 2). Challenge Virus Standard-
11 (CVS-11), a virulent neurotropic lyssavirus, was obtained
from the American Type Culture Collection (ATCC: refer-
ence VR959). CVS-11 was grown in baby hamster kidney
(BHK)-21 cells, as described previously [29].
Experimentally infected brain samples were prepared as
described next. Female Swiss outbred mice (Harlan, The
Netherlands) were inoculated intranasally at the age of 6 to
8 weeks, according to Rosseels et al. [29]. The experimental
procedure was approved by the Local Ethical Committee of
the WIV-ISP (advice nr. 060217-03). Sixty mice were each
inoculatedwith 3×102 50%TCID
50
ofCVS-11 and euthanized
by cervical dislocation from 0 to 10 days after inoculation
(DPI). Five control mice received only phosphate-buffered
saline (PBS). The evolution of the load of infectious virus,
viral antigen, and viral RNA was followed for 10 days. The
brain was cut in half and the inner part of the left half
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was pressed on a glass slide for FAT analysis. Both brain
halves were then homogenized in 1mL of PBS with a Potter
homogenator. The homogenate underwent 3 consecutive
freeze-thaw cycles at −80∘C and was centrifuged at 20000 g
for 20min at 4∘C. The supernatant was collected for virus
titration (300 𝜇L), RABV-specific qRT-PCR, and generic
lyssavirus qRT-PCR (2×85 𝜇L).Virus titrationwas performed
according to the instructions of the Manual of Diagnostic
Tests and Vaccines for Terrestrial Animals (Office Interna-
tional des Epizooties, 2013). Serial five-fold dilutions were
added in triplicate to BHK-21 cells. After a 2-day incubation
period, the cells were stained with fluorescein isothiocyanate
(FITC)-coupled antinucleocapsid rabbit antibodies (Bio-Rad
Laboratories, Hercules, USA) and the number of infected foci
was counted. The titre of infectious virus was expressed in
TCID
50
/mL.
2.2. Fluorescent Antibody Test (FAT). TheFATwas performed
according to the instructions of the Manual of Diagnostic
Tests and Vaccines for Terrestrial Animals (Office Interna-
tional des Epizooties, 2012). Briefly, the tissue slides were
fixed in 75% acetone for 10min at −20∘C and stained with
FITC-labelled antinucleocapsid rabbit antibodies (Bio-Rad
Laboratories, Hercules, USA) for 30min at 37∘C. The slides
were examined with a Nikon Diaphot 200 fluorescence
microscope connected to a Moticam 2500 camera (Hong-
Kong, China) at a magnification of 100x.
2.3. Generic Lyssavirus qRT-PCR
2.3.1. RNA Extraction. Total RNA from the various samples
was extracted using the Qiagen RNeasy Mini kit (for brain
and cell culture medium) or the Qiagen QIAamp viral RNA
Mini kit (for serum and CSF) (Qiagen, Hilden, Germany).
Brain samples (400mg) were first homogenised in 1mL of
PBS with a Potter homogenator. Eighty-five microliter of
the brain homogenate was mixed with 265𝜇L of lysis buffer
(RLT) and used for RNA extraction. From here on, the
instructions from the RNeasy Mini kit were followed. For
RNA extractions from infected cell culture supernatants, a
volumeof 150𝜇Lwas homogenised in 200𝜇LofRLTbuffer, as
startingmaterial for the RNA extraction. Starting from serum
or CSF, a volume of 140 𝜇L was used for RNA extraction
with the Qiagen QIAamp viral RNA Mini kit following the
manufacturer’s instructions.
2.3.2. Reverse Transcription. The RNA extracts were quan-
tified with a NanoVue spectrophotometer (GE healthcare,
Bucks, United Kingdom). The reverse transcription reaction
was performed using the qScript cDNA SuperMix (Quanta
BioSciences, Gaithersburg, USA). Briefly, 18𝜇L containing
100 ng of RNA template in RNAse-free water and 2 𝜇L of the
qScript supermixweremixed and incubated for 5min at 25∘C
followed by 30min at 42∘C and 5min at 85∘C.
2.3.3. Design of the Oligonucleotide Primers. The nucleo-
protein N gene was used as target for the qRT-PCR. The
primers were synthesized by Eurogentec (Seraing, Belgium).
The lyssavirus primers were chosen based on multiple align-
ments of the N gene sequence from RABV, LBV, MOKV,
DUVV, EBLV-1, EBLV-2, ABLV, WCBV, KHUV, and IRKV.
Complete sequences of the nucleoprotein gene of each
lyssavirus species were obtained from genomic databases and
aligned by using the MEGA5 and the CLC Sequence Viewer
software. The accession numbers of these viruses are shown
in Table 3(a). External and nested primer sequences were
chosen from regions conserved in all lyssavirus species. The
RAB PCR1 F, RAB PCR1 R, and RAB qPCR F primers were
designed in-house (Table 3(b)). The GRAB2R primer was
described earlier by Va´zquez-Moro´n et al. [30]. Degenerate
bases were included in the primers to account for the vari-
ability in the sequences of different lyssavirus species. A first
amplification round (PCR1) was performed using the RAB
PCR1 F and RAB PCR1 R primers, which amplify a fragment
of 343 bp of the N gene. 5 𝜇L of the PCR product was diluted
10x and then used in a real-time PCR with the RAB qRT-
PCR F and GRAB2R primers, amplifying a 158 bp fragment
within the first PCR amplicon. The RABV monospecific
primers (RAB CVS-11 F and RAB CVS-11 R) were designed
to specifically target the nucleoprotein N gene of CVS-11
(accession number GU992321). They contain no degenerate
bases (Table 3(b)). The primers VETINHF2 and VETINHR1
were designed in-house to amplify a conserved sequence of
the r18S ribosomal RNA gene and were usedto check for PCR
inhibition and RNA quality [31, 32]. They can be used for
samples from multiple animal species (Table 3(b)).
2.3.4. Nested qPCR. The protocol consisted of a nested PCR
strategywith two amplification steps. In the first amplification
round (PCR1), 5𝜇L of cDNA was mixed with a PCR master
mix containing 10 𝜇L of 5x reaction buffer, 1.5mM of MgCl
2
,
0.2 U Taq polymerase (Promega, Madison, USA), 0.5𝜇M
of the primers RAB PCR1 F and RAB PCR1 R, 0.2mM
of dNTP mix (Roche, Basel, Switzerland),and nuclease-free
water to obtain a final volume of 50 𝜇L. The amplification
was performed on an iCycler (Biorad, Hemel Hempstead,
United Kingdom) according to the following program: 1min
at 95∘C for initial denaturation, followed by 25 cycles of
20 s at 95∘C (denaturation) and 40 s at 60∘C (annealing and
extension), and a final step of 10min at 72∘C. The second
amplification consisted of a real-time PCR performed on a
CFX96 real-time PCR system (Biorad, Hemel Hempstead,
United Kingdom).The reactionmix consisted of 12.5 𝜇L of 2x
SyberGreen Master Mix (Quanta BioSciences, Gaithersburg,
USA), 5 𝜇L of 10x diluted PCR1 product and 0.8 𝜇M of each
primer (RAB qRT-PCR F and GRAB2R), and nuclease-free
water to obtain a final volume of 25 𝜇L. All samples were
analyzed in duplicate. The program consisted of 2min at
95∘C for Taq activation and initial denaturation, followed
by 45 cycles of 20 s at 95∘C and 30 s at 61∘C. To check for
the presence of primer dimers and nonspecific amplicons, a
melting curve analysis was performed after each run (Bio-
Rad CFX manager 2.1 software).
A total of 45 cycles were ran in the qPCR. The inter-
pretation of the qPCR results was done as follows: a sample
with a Cq value ≤40 was considered positive and a Cq value
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Table 3: (a) Accession numbers of analysed lyssavirus species. (b) Nucleotide sequence of the primers (with the IUPAC codes for the
degenerate bases) that were used in this study.
(a)
Rabies virus Identification GenBank accession number
RABV CVS-11 GQ918139
RABV 9174GSFRA U22474
RABV 9107MAR U22852
LBV LBVSA2006 EF547452
LBV U22842
MOKV NC006429
MOKV U22843
DUVV U22848
DUVV EU623438
EBLV-1 891FRA U22845
EBLV-1 8615POL U22844
EBLV-2 9007FIN U22846
EBLV-2 9018HOL U22847
ABLV AF006497
ARAV EF614259
ARAV AB094438
KHUV EF614261
IRKV EF614260
IRKV THChina12 JX442979
WCBV EF614258
SHV GU170201
BOKV 21961 JF311903
IKOV Isolate RV2508 JX193798
IKOV NC018629
(b)
Name Tm Sequence 5󸀠-3󸀠 Position (for RABV-CVS11) Use of primers
RAB PCR1 F 60,2∘C AYAARATGTGYGCIAAYTGGAGYA 572–595 Generic lyssavirus PCR1
RAB PCR1 R 61,8∘C ACIGCRTTSGANGARTAAGGAGA 892–914 Generic lyssavirus PCR1
RAB qPCR F 62,1∘C GTIGGVACDGTIGTIACHGCHTA 676–698 Generic lyssavirus qRT-PCR
GRAB2R 61∘C TCYTGHCCIGGCTCRAACAT 814–833 Generic lyssavirus qRT-PCR
RAB CVS11 F 68,1∘C GTGGGCACAGTCGTCACCGCTTA 676–698 RABV-specific qRT-PCR
RAB CVS11 R 60,85∘C TCTTGCCCTGGCTCGAACAT 814–833 RABV-specific qRT-PCR
VETINHF2 60,8∘C GTTGATTAAGTCCCTGCCCTTT / r18S qPCR
VETINHR1 60,8∘C GATAGTCAAGTTCGACCGTCTT / r18S qPCR
The r18S ribosomal RNA gene primers were designed to amplify RNA from multiple species.
>40 or an undetectable Cq was considered negative. Samples
with a Cq value between 40 and 45 were always retested. The
melting curve was analysed to check the specificity of the
amplification.
2.3.5. Sequencing Species Identification. The obtained ampli-
cons were purified using the GFX PCR DNA kit (GE Health-
care, PQ,USA) and quantifiedwith theNanoVue spectropho-
tometer (GEHealthcare, PQ,USA).The sequencing reactions
were performed using the RAB qRT-PCR F primer and the
big dye terminator v.3.1 cycle sequencing kit (Applied Biosys-
tem, CA, USA), according to themanufacturer’s instructions.
As starting material, 1–3 ng of the purified PCR fragment was
used. The cycle PCR reactions were performed on an iCycler
fromBiorad, programmed as follows: a first denaturation step
of 1min at 96∘C and 25 cycles consisting of 10 s at 96∘C and
4min at 60∘C. Final products were purified by precipitation
by adding 5 𝜇L of 125mMEDTA/sodium acetate 3M solution
and 60 𝜇L of ethanol 100%. The sequencing reactions were
analysed on an ABI Prism 3130 Genetic Analyzer (Applied
Biosystem, California, USA). The obtained sequences were
matched with the sequences stored in the National Center for
Biotechnology Information (NCBI) database, using the Basic
Local Alignment Search Tool (BLAST).
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Table 4: Comparison of the sensitivity between the two-step lyssavirus qRT-PCR and the one-step qRT-PCR published by Hayman et al. in
2011 [33].
Dilutions
RABV strain EBLV-1 strain
Two-step developed assay One-step published assay Two-step developed assay One-step published assay
Cq value Cq value Cq value Cq value
1.00𝐸 + 00 9.52 17.41 6.77 19.51
1.00𝐸 − 02 12.58 23.80 11.40 26.92
1.00𝐸 − 03 17.59 27.31 17.07 30.70
1.00𝐸 − 04 21.97 30.95 21.37 33.70
1.00𝐸 − 05 26.16 34.29 24.98 37.36
1.00𝐸 − 06 30.94 38.10 28.35 ND
1.00𝐸 − 07 34.30 ND ND ND
RNA was extracted from infected cell culture supernatants, serially diluted and used to generate cDNA. The cDNA samples were tested by both qRT-PCR
protocols. ND: no signal detected.
2.4. RABV-Specific qRT-PCR. The RABV-specific qRT-PCR
consisted of a single amplification step and was performed on
a CFX96 real-time system from Biorad (Hemel Hempstead,
United Kingdom). Each 25𝜇L reaction mixture consisted of
12.5 𝜇L of 2x Sybr Green Master Mix (Quanta BioSciences,
Gaithersburg, USA), 5𝜇L of diluted cDNA, and 0.4 𝜇M of
each primer. All samples were analyzed in duplicate. The
amplification program consisted of 2min initial denaturation
at 95∘C, followed by 45 cycles of 20 s at 95∘C and 30 s of
annealing and extension at 62∘C. A melting curve analysis
was performed in order to verify the absence of primer dimers
and the specificity of the obtained amplicons after each
run (Bio-Rad CFX manager 2.1 software). The correlation
between Cq values of both qRT-PCRmethods was calculated
with the Pearson’s correlation test (GraphPad Prism 6 soft-
ware).
3. Results
3.1. Diagnostic Sensitivity
3.1.1. Spectrum of Lyssavirus Detection. All positive samples
(𝑛 = 69) that contained either one of 7 different lyssavirus
species (Table 2) were tested positive with the lyssavirus qRT-
PCR, yielding a sensitivity of 100% for the assay. Some of the
rare species (WCBV, IRKV, KHUV, IKOV, SHIBV, and BBLV)
were not tested, but in silico alignment of the targeted region
in the nucleoprotein gene of these species demonstrated
a sufficient match with the degenerate primers to allow
amplification (Figure 1). No primer dimers were detected.
The obtained amplicons were also checked by agarose gel
analysis and had the expected size of 158 bp (data not shown).
To demonstrate the superior sensitivity of the two-step
approach, the lyssavirus qRT-PCR was compared with a pre-
viously published one-step lyssavirus qRT-PCR [33]. Serial
dilutions of 2 virus-positive samples from the 2013 annual
international proficiency test from ANSES (Nancy, France)
were compared. The samples contained a RABV isolate from
a dog (Canis lupus familiaris), or an EBLV-1 isolate from a bat
(Eptesicus serotinus). The virus-positive samples were diluted
ten-fold and tested by both protocols. The obtained results
are presented in Table 4. The two-step approach was 10 times
more sensitive than the one-step approach [33].
3.1.2. Comparison of the Course of an Experimental RABV
Virus Infection inMiceDetermined byGeneric Lyssavirus qRT-
PCR, RABV Monospecific qRT-PCR, and FAT. Mice were
inoculated intranasally with rabies virus and brain tissue
was sampled at different DPI for analysis. qRT-PCR results
were expressed in delta Cq values, which were calculated
as follows: 45 − Cqsample (45 = the total number of cycles
run in the qPCR). Viral RNA was first detected at 3 DPI
(mean delta Cq of 4.2), which was followed by an increase
of the viral RNA load at 5 DPI (mean delta Cq of 23.2
at 5 DPI) (Figure 2(a)). The viral load reached a plateau
from 7 DPI onwards (mean delta Cq of 26). Starting from
5 DPI, viral antigens could also be detected with the FAT
and small amounts of infectious virus could be isolated from
the brain (Figure 2(b)). At 5 DPI, the virus titer ranged
from 102 to 104 TCID
50
/mL. The titer increased during the
following days to reach a plateau, ranging between 104 and 106
TCID
50
/mL at 8 DPI (Figure 2(c)). The Cq values obtained
with the one-step monospecific qRT-PCR correlated well
with the values obtained with the two-step lyssavirus qRT-
PCR (Pearson value 𝑟 = 0.9773; 𝑃 < 0.001, GraphPad Prism
6) (Figure 2(d)). The generic lyssavirus qRT-PCR proved to
be more sensitive than the FAT. Eleven mice that tested
positive with the generic lyssavirus qRT-PCR at 3 and 4 DPI,
tested negative by the FAT. Uninfected control mice tested
negative with both qRT-PCR methods and the FAT.
3.2. Selectivity. For all samples, the sequence of the obtained
amplicon could be assigned unequivocally to the correct
species by comparing the nucleotide homology in the NCBI
database (BLAST, highly similar sequences). Homology was
in the range of 95–100% for RABV, MOKV, EBLV-1, EBLV-2,
and ABLV and in the range of 85–87% for LBV and DUVV.
Moreover, melting temperature profiles of the respective
amplicons differed for the different species and no primer
dimers were observed in any PCR run (Figure 3). The
vesicular stomatitis virus (VSV) tested negative (undetectable
Cq) with the generic lyssavirus qRT-PCR.
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Figure 1: Sequence alignment of the degenerate primers with the targeted region of the nucleoprotein gene of 24 isolates of 14 different
lyssavirus species.
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Figure 2: Kinetic profile of RABV infection in mice determined by generic lyssavirus qRT-PCR, FAT and virus titration. Mice were infected
with 3 × 102 TCID
50
of RABV (CVS-11) by intranasal inoculation and sacrificed 0 to 10 days later. The brain was collected for analysis. The
course of (a) viral RNA by generic lyssavirus qRT-PCR, (b) load of viral antigen (FAT), (c) infectious virus (RTCIT), and (d) correlation of Cq
values between the generic lyssavirus and RABV-specific qRT-PCR are presented. The correlation between the Cq values obtained by both
qRT-PCR methods was excellent (Pearson’s correlation coefficient 𝑟 = 0.9773, 𝑃 < 0.0001).
3.3. Limit of Detection. The limit of detectionwas determined
by analysing 10-fold serial dilutions of a suspension of
RABV (CVS-11) and EBLV-1. RABV and EBLV-1 suspensions
were produced in BHK-21 and neuroblastoma N2a cells,
respectively. The titer of infectious virus was determined in
cell culture.The virus was diluted from 106 to 10−2 TCID
50
for
RABV and from 104 to 10−2 TCID
50
for EBLV-1. For RABV,
the viral RNA load was determined by both the generic
and the RABV-specific qRT-PCR, while for EBLV-1, only
the generic lyssavirus qRT-PCR was used. The obtained Cq
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Figure 3: Melting peaks obtained for 7 lyssavirus species. The
melting temperatures for RABV, MOKV, LBV, DUVV, EBLV-1, -
2, and ABLV were, respectively, 77∘C, 77.5∘C, 76∘C, 76.5∘C, 78.5∘C,
78∘C, and 76.5∘C. No primer dimers were observed.
values correlated well with the logarithm of the correspond-
ing TCID
50
values using a linear fit model (GraphPad Prism
6) (Figure 4(a)).
The limit of detection for RABV was 100 TCID
50
for
both qRT-PCR methods, with 100% positive replicates (6
different runs in duplicate). At the 10−1 TCID
50
and 10−2
TCID
50
dilutions, all replicates were negative (Cq value > 40
or undetectable) with the generic lyssavirus qRT-PCR. For
the RABV monospecific qRT-PCR, 8 replicates were positive
and 4 replicates were negative at the 10−1 TCID
50
dilution.
At the 10−2 TCID
50
dilution, 4 replicates were positive and
8 replicates were negative with the RABV-specific qRT-PCR
(Figure 4(a)). Negative control samples (viral RNA substi-
tuted by water) gave no signal with both qRT-PCR methods.
The detection limit of EBLV-1 was determined at 10−1 TCID
50
for the generic lyssavirus qRT-PCR. At 10−1 TCID
50
, all
replicates yielded positive results. At 10−2 TCID
50
, 5 replicates
yielded positive and 7 replicates yielded negative results (Cq
value > 40 or undetectable) (Figure 4(b)).
The two-step protocol was also compared with a one-step
qPCR round based on the same PCR1 or qPCRprimers, using
samples from the 2011 and 2013 annual ring test from ANSES
(Nancy, France). A sample containing an ABLV isolate from
an Australian bat (Pteropus Alecto) was diluted 1/10, 1/100,
1/500, and 1/1000 and a sample containing a RABV isolate
from a European red fox (Vulpes vulpes) was diluted 1/8,
1/100, and 1/500. All dilutions tested positive with the two-
step protocol. Depending on the dilution, Cq values ranged
from 16 to 24. In contrast, the one-step protocol gave either no
signal or high Cq values, ranging between 31 and 44 (data not
shown). This underlines the need for the two amplification
rounds to obtain acceptable sensitivity.
3.4. Diagnostic Specificity. The diagnostic specificity was
100%. A total of 150 brains of rabies virus-free mammals,
belonging to 5 different species, tested negative by FAT and
generic lyssavirus qRT-PCR (Table 1). Ten human cerebro-
spinal fluid samples, 6 saliva samples, and 1 skin biopsy
obtained from rabies-free patients with neurological symp-
toms tested negative by qRT-PCR, yielding a diagnostic
specificity of 100%. The qRT-PCR always yielded negative
results upon substitution of the RNA by water in the different
steps of the protocol (RNA extraction, reverse transcription,
and two-step qPCR).
3.5. Repeatability (Intra-Assay Variation). To assess the intra-
assay variation, 3 samples (CVS-11, EBLV1, and water as a
negative control) were tested in 10 replicates. The variation
coefficient (Pearson r-GraphPad Prism 6) was 1.7% for CVS-
11 (at a mean Cq of 21.5) and 0.89% for EBLV-1 (at a mean
Cq of 24.3). The negative control remained undetectable in
all replicates.
3.6. Reproducibility (Inter-Assay Variation). The inter-assay
precision was assessed by testing 3 samples (CVS-11, EBLV-
1, and water as a negative control) in 6 independent runs
(Figure 4). The virus suspensions were diluted from 106 to
10
−2 TCID
50
for CVS-11 and from 104 to 10−2 TCID
50
for
EBLV-1.The Cq values increased with the viral load.The 95%
confidence interval was calculated for all CVS-11 and EBLV-1
tested dilutions (Figure 4(c)).
3.7. Matrix Effect. Brain tissue is the preferred specimen for
postmortem diagnosis in both humans and animals, but this
sample is not feasible for antemortem diagnosis. In the latter
case, diagnosis is based on detection of virus or viral RNA
in saliva, neck skin biopsy, or an impression of the cornea.
To validate the generic lyssavirus qPCR on other matrices
than brain tissue, CSF, saliva, and urine were spiked with
different virus doses, ranging from 105 to 10−1 TCID
50
for
RABV (CVS-11) and from 104 to 10−2 TCID
50
for EBLV-1.
Each samplewas analysed in 3 different runs (RNA extraction
followed by qPCR) and results were expressed in mean
Cq values (Table 5). PCR inhibition and RNA quality were
checked by using r18S ribosomal RNA gene amplification.
Virus could be detected in all testedmatrices (saliva, CSF, and
urine). The limit of detection for EBLV-1 was 100 TCID
50
in
CSF, saliva, and urine. The limit of detection for RABV was
also 100 TCID
50
in urine but appeared higher in CSF (101
TCID
50
) and in saliva (102 TCID
50
).
4. Discussion
Real-time PCR provides significant methodological benefits
for virus detection [34]. RT-PCR offers many advantages
for rabies diagnosis, due to its high sensitivity, rapidity, no
interference by inhibitors of virus infectivity or antibodies,
practicability for samples which may contain only minute
amounts of virus, such as cerebrospinal fluid or bat brain, and
the possibility to quickly determine the species andmolecular
phylogeny of the isolate. Several RT-PCR protocols for the
detection of rabies virus have been published during the
past decade. All protocols that recognise multiple lyssavirus
species use degenerate primers [30, 33, 35–39] and most of
them use the JW12 primer published by Heaton et al. 1997
[35]. A cocktail of nondegenerate/degenerate primers is only
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Figure 4: Analytical sensitivity of the monospecific RABV and the generic lyssavirus qRT-PCR for RABV (CVS-11) (a) and EBLV-1 (b).
Six independent runs with each time two repeats were performed per virus dilution (10-fold serial dilution). There was an excellent linear
regression between the load of infectious virus, determined by virus titration, and the Cq value for RABV and EBLV-1 (regression coefficient
of 0.965 and 0.989, resp.). For both qRT-PCR methods, the limit of detection of RABV and EBLV-1 was ≤ 100 TCID
50
. The Cq remained
undetectable in the negative control samples.∗Mean and standard deviation are calculated based on the runs/repeats with a positive signal
(Cq ≤ 40). ND = not determined.
used in the protocols published by Heaton et al. in 1997 [35]
and Black et al. in 2003 [36]. Three protocols are designed as
a two-step PCR and all of them use a gel-based DNA system
detection [30, 35, 39] while others are real-time one-step
protocols [33, 36–38]. Only two protocols were validated for
7 species [30, 33]. The RT-PCR of Va´zquez-Moro´n et al. [30]
uses a nested classical PCR system with degenerate primers
and a gel-based DNA detection system. Real-time RT-PCR
is however a more rapid and potentially more sensitive
technique [34, 40]. Recently, Hayman et al. [33] validated
the use of a real-time RT-PCR protocol for the detection of
7 lyssavirus species. They used a set of mildly degenerate
primers that contained one or two degenerate bases per
primer and were originally designed for the recognition of
RABV, EBLV-1, and -2.
In this study, a two-step generic lyssavirus qRT-PCR,
capable of detecting 7 lyssavirus species (RABV, LBV,MOKV,
DUVV, EBLV-1, EBLV-2, and ABLV), was developed and
validated.The two-step approach allowsmaximumsensitivity
in order to detect virus in typically small-size samples, such
as bat brains or samples which contain only minute amounts
of virus, such as CSF. A good in silico match of the primers
with the N gene of the remaining 6 species (WCBV, IRKV,
KHUV, IKOV, SHIBV, and BBLV) was also demonstrated.
A cocktail of primers with 17 to 30% of degenerate bases,
taking into account the variability of the different lyssavirus
species, was designed for the assay. The primers target well-
conserved regions of the N gene. Indeed, ample sequence
data are available for the N gene and most of the published
RT-PCR protocols use primers for the N gene [30, 33, 36–
39, 41–43]. A large set of samples obtained from wild and
domestic animals (bat, red fox, dog, and cat), human patients
with nonrabies encephalitis, interlaboratory ring trials, and
naturally and experimentally infected animals (bat andmice)
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Table 5: Effect of the matrix on qRT-PCR performance.
(a)
RABV (TCID50) CSF Saliva Urine
1.00𝐸 + 05 19.65 18.80 18.53
1.00𝐸 + 04 24.50 23.39 23.13
1.00𝐸 + 03 28.12 27.17 26.85
1.00𝐸 + 02 33.15 32.75 30.56
1.00𝐸 + 01 40.53 ND 39.67
1.00𝐸 + 00 43.54 ND 39.78
1.00𝐸 − 01 ND ND ND
1.00𝐸 − 02 ND ND ND
(b)
EBLV-1 (TCID50) CSF Saliva Urine
1.00𝐸 + 04 14.56 15.31 14.50
1.00𝐸 + 03 18.11 18.34 18.84
1.00𝐸 + 02 22.72 23.79 22.17
1.00𝐸 + 01 27.74 28.90 28.06
1.00𝐸 + 00 33.10 28.17 28.67
1.00𝐸 − 01 ND ND ND
1.00𝐸 − 02 ND ND ND
Saliva, CSF, and urine samples were spiked with decreasing doses of RABV
or EBLV-1. Three independent runs with each time two repeats were
performed per virus dose (10-fold serial dilution). The limit of detection for
RABVwas 100 TCID50 in urine, 10
1 TCID50 inCSF, and 10
2 TCID50 in saliva.
For EBLV-1, the limit of detection was 100 TCID50 in CSF, saliva, and urine.
ND: signal not detected.
was tested. To check for PCR inhibition and RNA quality,
the cellular r18S ribosomal RNA gene was used as a target.
The r18S ribosomal RNA has been shown to be more reliable
than 𝛽-actin [42, 44]. The diagnostic specificity was 100%
and sensitivity proved superior to the fluorescent antigen
test. The limit of detection was ≤1 TCID
50
. Sequence analysis
of the amplicon unequivocally assigned the correct species.
The vesicular stomatitis virus (belonging to the related genus
Vesiculovirus) was not recognized, confirming the selectivity
of the degenerate primers.
This qRT-PCR protocol is now routinely used for rabies
surveillance in Belgium. Since 2001, Belgium has been offi-
cially declared free of the classic rabies virus. However, bats
are an important reservoir of lyssaviruses in Europe [45] and
are still collected and tested in the frame of the Belgian rabies
surveillance system [46].
In experimentally infected mice, viral RNA was first
detected at 3DPI in the brain, whereas first symptoms
appeared much later at 8DPI. Symptoms involved depres-
sion, loss of body weight, ruffled fur, and paralysis of the hind
limbs. In general, results of the generic lyssavirus qRT-PCR,
RABV-specific qRT-PCR, virus titration, and FAT correlated
well and provided similar kinetic profiles throughout the
infection.The qRT-PCR proved however to bemore sensitive
than virus titration and FAT. Indeed, 11 out of 55 mice tested
negative by FAT and positive by qRT-PCR. Also, 11 out
55 qRT-PCR-positive mice tested negative by RTCIT. Cycle
thresholds obtained by the generic and the RABV-specific
qRT-PCR were highly correlated.
The virus species in the positive samples could be
identified by sequencing. For some species, we observed
different melting temperatures and curves, providing an
early indication of the species prior to sequencing. The
melting temperature, determined with the CFX96 system
from Biorad, was different for RABV, LBV, MOKV, EBLV-
1, and EBLV-2, whereas DUVV and ABLV had the same
melting temperature (Figure 3). The number of strains tested
per species was however insufficient to accurately define the
melting curve differentiation. It is also possible to obtain a
more precise calculation by high resolutionmelt analysis [47],
whichmay theoretically allow to discriminate all species prior
to sequencing. This was not done for this study.
To further assess the exactitude of our qPCR method,
we participated to the consecutive international ring trials
organised by ANSES (Nancy, France) from 2009 to 2013. Up
to now, we reported very good compliant results in each trial.
Moreover, we participated in the Epizone ring trial organised
by the Friedrich-Loeffler-Institute (FLI, Germany) in 2011.
The panel consisted of 30 samples prepared by the FLI and
included RNA of 26 RABV isolated in different countries and
years, an EBLV-1 and an EBLV-2 RNA sample, and a log10
serial dilution of RABV. We correctly reported all negative
samples and 28 of the 30 positive samples, representing a
sensitivity of 93.3%. Two samples with a Cq value >40 were
considered as negative samples. These two false negatives
could have been due to the fact that the samples were
extracted and prepared in RSB50, a buffer different from
the one used in our protocol. The RSB50 buffer contains
the carrier poly A, which forced us to use a gene-specific
reverse transcription kit (qScript Flex cDNA Synthesis kit,
Quanta BioSciences, Gaithersburg, USA). Only 3 of the 16
laboratories submitted 100% concordant results for RABV
diagnosis [48].
Despite the presence of 17 to 30% of degenerate bases
in some of the primers, the lyssavirus qRT-PCR proved
to be highly sensitive, specific, and reproducible. In our
national reference laboratory, this technique is now used as
the method of choice for antemortem rabies diagnosis and
analysis of small-size samples, such as bat brain.
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